The row we do not tick
Teriparatide sits in the table with no green mark, because 0.08 mL has no direct equivalent in our released range. We could have left the row out. Listing it is more useful to you: if your program is a short-travel, high-resolution dose, that is a tooling conversation to have at the first call rather than a discovery at validation.
The same honesty applies in the other direction. "Covered" here means the travel range can reach your dose volume. It does not mean the platform is qualified for your product — that requires feasibility samples, dose accuracy testing to ISO 11608-1 and a joint validation plan.
What this page is not
This is a device capability comparison, not a therapeutic claim. Nothing here states that a webosan pen is indicated for, or approved with, any medicine. Dose regimens are governed by the approved labelling in your market, and the device decision follows from your fill volume, concentration and target increment — confirmed per program.